Article
CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations.
Bone marrow transplantation - 1 Apr 2020
Jin Aiyun, Feng Jingjing, Wei Guoqing, Wu Wenjun, Yang Luxin, Xu Huijun, Zhang Yanlei, Cui Jiazhen, Chang Alex Hongsheng, Hu Yongxian, Huang He
Abstract excerpt
Treatment of acute lymphoblastic leukemia (ALL) is still a challenge despite years of researching, especially for those of poor prognosis. Zhang and his team recently proved that FLT3 gene mutation was identified in ~5% of ALL and the mutation spectrum is different from AML. Recently, chimeric antigen receptor T cells (CART) therapy presents great efficacy in treating refractory leukemia. We report a case of a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.